Meeting
2021 Genitourinary Cancers Symposium
Phase II study of the oral hypoxia-inducible factor 2α (HIF-2α) inhibitor MK-6482 for Von Hippel-Lindau (VHL) disease-associated clear cell renal cell carcinoma (ccRCC).
Authors
Othon Iliopoulos
Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA
Othon Iliopoulos , Eric Jonasch , Frede Donskov , Vivek Narayan , Benjamin Louis Maughan , Stephane Oudard , Tobias Else , Jodi K. Maranchie , Sarah J. Welsh , Sanjay Thamake , Rodolfo F. Perini , Eric Kristopher Park , W. Marston Linehan , Ramaprasad Srinivasan , W. Kimryn Rathmell
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session: Renal Cell Cancer
Track
Renal Cell Cancer
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT03401788
Citation
J Clin Oncol 39, 2021 (suppl 6; abstr 333)
DOI
10.1200/JCO.2021.39.6_suppl.333
Abstract #
333
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Phase 2 study of belzutifan (MK-6482), an oral hypoxia-inducible factor 2α (HIF-2α) inhibitor, for Von Hippel-Lindau (VHL) disease-associated clear cell renal cell carcinoma (ccRCC).
First Author: Ramaprasad Srinivasan
Poster
2019 Genitourinary Cancers Symposium
An open-label phase II study to evaluate PT2977 for the treatment of von Hippel-Lindau disease-associated renal cell carcinoma.
First Author: Eric Jonasch
Poster
2023 ASCO Annual Meeting
Belzutifan treatment of Von Hippel-Lindau (VHL) related central nervous system (CNS) hemangioblastomas (HBs): A single institution experience.
First Author: Othon Iliopoulos
Poster
2023 ASCO Genitourinary Cancers Symposium
Burden of surgeries and surgical complications in patients with Von Hippel Lindau (VHL) disease before and after treatment with belzutifan.
First Author: Lin Wang